Down 20%: Ariad Pharmaceuticals' Second Dose of Bad News

Earlier this week, news of a safety issue with Ariad Pharmaceuticals' leukemia drug Iclusig caused the drugmaker's shares to plunge more than 65%. Today, the stock took another 20% tumble after the FDA announced that it is investigating the safety problems associated with the medication. In the following video, health-care analysts Max Macaluso and David Williamson discuss the details behind both of Ariad's drops this week.

Incredible growth stock to watch today
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!

The article Down 20%: Ariad Pharmaceuticals' Second Dose of Bad News originally appeared on Fool.com.

Alison Southwick has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.